Show simple item record

2019-05-09Zeitschriftenartikel DOI: 10.25646/6245
Piloting a surveillance system for HIV drug resistance in the European Union
dc.contributor.authorvan de Laar, Marita J. W.
dc.contributor.authorBosman, Arnold
dc.contributor.authorPharris, Anastasia
dc.contributor.authorAndersson, Emmi
dc.contributor.authorAssoumou, Lambert
dc.contributor.authorAy, Eva
dc.contributor.authorBannert, Norbert
dc.contributor.authorBartmeyer, Barbara
dc.contributor.authorBrady, Melissa
dc.contributor.authorChaix, Marie-Laure
dc.contributor.authorDescamps, Diane
dc.contributor.authorDauwe, Kenny
dc.contributor.authorFonager, Jannik
dc.contributor.authorHauser, Andrea
dc.contributor.authorLunar, Maja
dc.contributor.authorMezei, Martha
dc.contributor.authorPoljak, Mario
dc.contributor.authorvan Sighem, Ard
dc.contributor.authorVerhofstede, Chris
dc.contributor.authorAmato-Gauci, Andrew
dc.contributor.authorBroberg, Eeva K.
dc.date.accessioned2019-09-04T11:10:55Z
dc.date.available2019-09-04T11:10:55Z
dc.date.issued2019-05-09none
dc.identifier.other10.2807/1560-7917.ES.2019.24.19.1800390
dc.identifier.urihttp://edoc.rki.de/176904/6263
dc.description.abstractBackground A steady increase in HIV drug resistance (HIVDR) has been demonstrated globally in individuals initiating first-line antiretroviral therapy (ART). To support effective use of ART and prevent spread of HIVDR, monitoring is essential. Aim We piloted a surveillance system for transmitted HIVDR to assess the feasibility of implementation at the European level. Method All 31 countries in the European Union and European Economic Area were invited to retrospectively submit data on individuals newly diagnosed with HIV in 2015 who were tested for antiviral susceptibility before ART, either as case-based or as aggregate data. We used the Stanford HIV database algorithm to translate genetic sequences into levels of drug resistance. Results Nine countries participated, with six reporting case-based data on 1,680 individuals and four reporting aggregated data on 1,402 cases. Sequence data were available for 1,417 cases: 14.5% of individuals (n = 244) showed resistance to at least one antiretroviral drug. In case-based surveillance, the highest levels of transmitted HIVDR were observed for non-nucleoside reverse-transcriptase inhibitors (NNRTIs) with resistance detected in 8.6% (n = 145), followed by resistance to nucleoside reverse-transcriptase inhibitors (NRTI) (5.1%; n = 85) and protease inhibitors (2.0%; n = 34). Conclusion We conclude that standard reporting of HIVDR data was feasible in the participating countries. Legal barriers for data sharing, consensus on definitions and standardisation of interpretation algorithms should be clarified in the process of enhancing European-wide HIV surveillance with drug resistance information.eng
dc.language.isoengnone
dc.publisherRobert Koch-Institut
dc.rights(CC BY 3.0 DE) Namensnennung 3.0 Deutschlandger
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/de/
dc.subjectHIV/AIDSeng
dc.subjectpilot studyeng
dc.subjectresistanceeng
dc.subjectsurveillanceeng
dc.subject.ddc610 Medizin und Gesundheitnone
dc.titlePiloting a surveillance system for HIV drug resistance in the European Unionnone
dc.typearticle
dc.identifier.urnurn:nbn:de:kobv:0257-176904/6263-2
dc.identifier.doihttp://dx.doi.org/10.25646/6245
dc.type.versionpublishedVersionnone
local.edoc.container-titleEurosurveillancenone
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttps://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2019.24.19.1800390#html_fulltextnone
local.edoc.container-publisher-nameInstitut de Veille Sanitairenone
local.edoc.container-volume24none
local.edoc.container-issue19none
local.edoc.container-reportyear2019none
local.edoc.container-year2019none
local.edoc.container-firstpage1none
local.edoc.container-lastpage7none
local.edoc.rki-departmentInfektionskrankheitennone
dc.description.versionPeer Reviewednone

Show simple item record